Lv11
50 积分 2025-07-08 加入
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
2天前
已完结
Systematic evaluation of dose accumulation studies in clinical pharmacokinetics
23天前
已完结
STEAP1-targeted strategies in advanced prostate cancer: a review on therapeutic and diagnostic implications
29天前
已完结
Preclinical characterization of ARX517, a site-specific stable PSMA-targeted antibody-drug conjugate for the treatment of metastatic castration-resistant prostate cancer
29天前
已完结
Therapeutic advances with KRASG12C inhibitors and combination strategies in non-small cell lung cancer brain metastases
1个月前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1个月前
已完结
抗肿瘤药物申报联合用药早期临床试验的考虑
2个月前
已完结
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial
3个月前
已完结
Clinical implementation of soluble EGFR (sEGFR) as a theragnostic serum biomarker of breast, lung and ovarian cancer
6个月前
已关闭
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
6个月前
已完结
皖公网安备34019202002308
